If You Invested in Biosyent (BIOYF)
Looking for the current price? See the BIOYF quote & overviewWhat $1,000 or $10,000 in BIOYF Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Jul 28, 2015 |
|---|---|---|---|---|
| $1,000 | $1,253 +25% | $1,740 +74% | $1,685 +69% | $1,986 +99% |
| $10,000 | $12,530 +25% | $17,396 +74% | $16,852 +69% | $19,862 +99% |
Based on real historical closing prices, dividend- and split-adjusted, through 2026-07-24. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for BIOYF$1,000 Investment Over Time
BIOYF vs S&P 500Year-by-Year Returns
BIOYF annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2017 | $5.73 | $7.33 | +27.9% | +27.9% |
| 2018 | $7.62 | $5.69 | -25.3% | -0.7% |
| 2019 | $5.69 | $4.45 | -21.9% | -22.4% |
| 2020 | $4.46 | $6.02 | +34.8% | +5.1% |
| 2021 | $5.96 | $6.33 | +6.1% | +10.4% |
| 2022 | $6.33 | $5.21 | -17.7% | -9.1% |
| 2023 | $5.41 | $6.96 | +28.7% | +21.5% |
| 2024 | $6.89 | $7.64 | +10.9% | +33.4% |
| 2025 | $7.73 | $9.52 | +23.2% | +66.2% |
| 2026 | $9.34 | $10.40 | +11.3% | +81.6% |
About Biosyent
Healthcare · OTC Link
BioSyent Inc. (OTC: BIOYF), referred to as "BioSyent" or the "Company" in its public communications, is a specialty pharmaceutical company in the healthcare and medicinal products space. According to the company, it is a profitable, growth-oriented business that focuses on in-licensing or acquiring pharmaceutical and other healthcare products that have already been successfully developed, shown to be safe and effective, and demonstrated a proven track record of improving the lives of patients.
BioSyent is listed on the TSX Venture Exchange under the trading symbol RX. The company describes itself as concentrating on products that are established in terms of development and safety profile, rather than early-stage research. Its strategy emphasizes bringing these products into its portfolio through in-licensing or acquisition, and then supporting their use in appropriate patient populations.
Business Focus and Model
In its public disclosures, BioSyent states that it is a specialty pharmaceutical company with a focus on growth and profitability. The company’s core business model is based on:
- In-licensing innovative pharmaceutical and healthcare products that have already been developed and evaluated
- Acquiring such products to add to its portfolio
- Concentrating on products that are described as safe, effective, and beneficial to patients
Rather than emphasizing early-stage discovery or basic research, BioSyent focuses on products that have a documented history of use and outcomes. The company positions these products within its commercial structure and supports healthcare professionals who prescribe or recommend them.
Healthcare Professional Support and Commercial Structure
BioSyent indicates that it supports the healthcare professionals who treat patients using its products. According to the company, this is done by marketing its portfolio through three main business units:
- Community business unit
- Specialty business unit
- International business unit
Through these units, BioSyent organizes its commercial activities across different channels and markets. The community and specialty units reflect different types of healthcare settings and professional audiences, while the international unit reflects activity outside its home market as indicated in its disclosures.
Capital Markets Presence
BioSyent’s common shares trade on the TSX Venture Exchange under the symbol RX. In its public communication, the company notes that it is a profitable and growth-oriented enterprise. It also discloses the number of common shares outstanding as part of its investor information, underscoring its status as a publicly traded issuer.
The company’s participation in investor conferences, such as the LD Micro Invitational XV Conference in New York City, further illustrates its engagement with the investment community. In these settings, BioSyent presents its business model, product focus, and growth orientation to current and potential shareholders.
Risk and Forward-Looking Information
In its press releases, BioSyent cautions that some of its statements may be forward-looking and subject to risks and uncertainties. The company notes that potential risks may include matters related to clinical trials, product development, future revenue, operations, profitability, and obtaining regulatory approvals. These disclosures are intended to inform investors that actual outcomes may differ from expectations described in forward-looking statements.
Position Within the Healthcare and Pharmaceutical Space
Based on the company’s own description, BioSyent operates as a specialty pharmaceutical business that concentrates on products with an established development and safety profile. Its focus on in-licensing and acquisition of such products, combined with its community, specialty, and international business units, defines how it approaches growth and patient impact.
By targeting products that already have a record of improving patient lives, BioSyent positions itself as a company that builds on proven healthcare solutions and supports the professionals who use them. Its communications emphasize profitability and growth orientation, while also acknowledging the regulatory and operational risks inherent in the pharmaceutical and healthcare sectors.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Biosyent investment returns
How much would $1,000 invested in Biosyent be worth today?
If you invested $1,000 in Biosyent (BIOYF) 10 years ago on 2016-07-27, your investment would be worth $1,685 as of 2026-07-24, representing a +68.5% total return, growing at a compounded rate of 5.4% per year (CAGR).
Has Biosyent outperformed the S&P 500?
Over the past 10 years, BIOYF returned +68.5% compared to +291.4% for the S&P 500, underperforming the benchmark by 222.9 percentage points.
What is Biosyent's average annual return?
The compound annual growth rate (CAGR) of BIOYF over the past 10 years is 5.4%, growing at a compounded rate each year. Individual years vary significantly — BIOYF's best recent year was 2020 (+34.8%) and worst was 2018 (-25.3%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
